AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Oramed Pharmaceuticals, a penny stock with a market cap of $122.59M, presents an intriguing case due to its robust financial position and recent profitability. The company is debt-free with short-term assets of $136.1M comfortably covering both short- and long-term liabilities. Oramed's earnings surged by 882.1% over the past year, outpacing industry averages, while maintaining a low price-to-earnings ratio of 2.8x compared to the broader US market's 19x. Despite limited revenue streams ($2M), its strategic Rights Agreement and dividend declaration signal confidence in future growth prospects.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet